Riyadh - Sharikat Mubasher: The Egypt-based pharmaceutical company, EVA Pharma, plans to launch its operations in the Saudi market through its manufacturing complex by the end of 2025, according to CEO Riad Armanious.

As one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), EVA Pharma aims to capture 4.5% of the Saudi pharmaceutical market and export 15% of its production from the Kingdom by 2030, Armanious stated in an interview with Asharq Business.

He explained that the first phase of the complex will consist of three pharmaceutical factories with four production lines dedicated to oncology medications. The complex is expected to meet approximately 6% of Saudi Arabia’s annual medication import needs.

In September, EVA Pharma signed an agreement with the Saudi Authority for Industrial Cities and Technology Zones (Modon) to attain a 50,517 square meters plot of land in Sudair City, for its state-of-the-art research and manufacturing complex in the Kingdom.

The industrial complex will cater to a diverse spectrum of therapeutic domains with plans to launch over 150 pharmaceutical products spanning biologics, vaccines, immunosuppressants, oncology, and high-potency medications, which require specialized containment technology.  

With a research and development (R&D) center at the heart of its industrial complex, EVA Pharma will bring the latest medical advancements closer while helping it respond more accurately to changing patient needs through research and collaboration with local universities and hospitals.

The industrial complex is scheduled to reach full operational capacity in 2026, producing 990 million units annually and offering 807 employment opportunities, ultimately contributing to the local economy.

Moreover, the complex will comprise five pharmaceutical factories, including one for biologics and oncology products, another for oral dosage forms like DPIs, Bi-layer, and ODT, an immunosuppressants facility, and a vaccines production unit.